Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Author:
Publisher
Elsevier BV
Reference25 articles.
1. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010
2. Cancer statistics 2009;Jemal;CA Cancer J Clin,2009
3. Epidemiology of prostate cancer in Asian countries;Kimura;Int J Urol,2018
4. The incidence and mortality of prostate cancer and its relationship with development in Asia;Pakzad;Prostate Int,2015
5. Cancer statistics in China, 2015;Chen;CA A Cancer J Clin,2016
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sex differences in the cardiovascular effects of GnRH analogues;Journal of Endocrinology;2024-01-24
2. A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy;Japanese Journal of Clinical Oncology;2023-07-05
3. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis;Frontiers in Endocrinology;2023-03-31
4. Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial;Anticancer Research;2023-03-27
5. Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study;Investigative and Clinical Urology;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3